John Johnston - Midatech Pharma Non-Executive Director
| MTPDelisted Stock | USD 1.14 0.26 18.57% |
Director
Mr. John Joseph Johnston was NonExecutive Director of Midatech Pharma PLC. Mr Johnston is currently nonexecutive director of Flowgroup plc, Action Hotels and prior to this, was managing director of Institutional Sales at Nomura Code. He was previously director of Sales and Trading at Seymour Pierce from 2008 to 2011. In 2003, Mr. Johnston founded Revera Asset Management, where he oversaw an investment trust, a unit trust and a hedge fund, which he ran until 2007. From 1992 to 1997, Mr. Johnston was Head of Small Companies at Scottish Amicable, before spending a year at Ivory and Sime, again as Head of Small Companies from 1997 to 1998. He joined Legg Mason Investors for three years as Director of Small Companies Technology and VC Trusts, from 2000 to 2003, having previously spent two years as Head of Small Companies with Murray Johnstone
| Phone | 44 29 2048 0180 |
| Web | https://www.midatechpharma.com |
Midatech Pharma Management Efficiency
The company has Return on Asset of (0.525) % which means that on every $100 spent on assets, it lost $0.525. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.9547) %, meaning that it generated no profit with money invested by stockholders. Midatech Pharma's management efficiency ratios could be used to measure how well Midatech Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Jillian Evanko | Parker Hannifin | 42 | |
| Gustavo Cisneros | Barrick Gold Corp | 74 | |
| Klaus Zeitler | Western Copper and | 77 | |
| Kenneth Williamson | Western Copper and | 69 | |
| Robert Bohn | Parker Hannifin | 66 | |
| Ted Gardner | Summit Materials | 61 | |
| Michael Evans | Barrick Gold Corp | 60 | |
| Henry Alpert | Griffon | 73 | |
| Arthur Anton | Olympic Steel | 60 | |
| Kevin Sullivan | Griffon | 67 | |
| Steven Shapiro | Barrick Gold Corp | 65 | |
| Dirk Kempthorne | Olympic Steel | 66 | |
| Kevin Lobo | Parker Hannifin | 55 | |
| Bradley Gross | Griffon | 45 | |
| James Verrier | Parker Hannifin | 57 | |
| William Waldorf | Griffon | 82 | |
| Karl Voltaire | Barrick Gold Corp | 63 | |
| Tara Christie | Western Copper and | N/A | |
| Idalene Kesner | Olympic Steel | 60 | |
| David Williams | Western Copper and | N/A | |
| Joseph Scaminace | Parker Hannifin | 67 | |
Management Performance
| Return On Equity | -0.95 | |||
| Return On Asset | -0.52 |
Midatech Pharma PLC Leadership Team
Elected by the shareholders, the Midatech Pharma's board of directors comprises two types of representatives: Midatech Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Midatech. The board's role is to monitor Midatech Pharma's management team and ensure that shareholders' interests are well served. Midatech Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Midatech Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Craig Cook, COO / Chief Medical Officer | ||
| Stephen Stamp, CFO, CEO | ||
| Frederic Duchesne, Non-Executive Director | ||
| BSc MBIOL, Head Manufacturing | ||
| Tim Sparey, Chief Bus. Officer | ||
| David Benharris, Pres Inc | ||
| Fiona Sharp, Group Controller | ||
| Paul Protopapas, Non-Executive Director | ||
| Huaizheng Peng, Director | ||
| Dmitry MD, Chief Officer | ||
| Rolf Stahel, Non-Executive Chairman of the Board | ||
| Simon Turton, Senior Independent Non-executive Director | ||
| Nicholas RobbinsCherry, Finance Director, Director | ||
| Daniel MBA, VP Technology | ||
| Vincent Holmes, VP Operations | ||
| John Johnston, Non-Executive Director | ||
| Michele Luzi, Non-Executive Director | ||
| James Phillips, CEO, Director | ||
| Daniel Palmer, Chief Scientific Officer | ||
| Simon Vries, Non-Executive Director | ||
| Justin Barry, Head - Manufacturing |
Midatech Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Midatech Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.95 | |||
| Return On Asset | -0.52 | |||
| Operating Margin | (11.69) % | |||
| Current Valuation | (117.06 K) | |||
| Shares Outstanding | 6.93 M | |||
| Shares Owned By Institutions | 4.00 % | |||
| Number Of Shares Shorted | 84.86 K | |||
| Price To Earning | (1.02) X | |||
| Price To Book | 0.65 X | |||
| Price To Sales | 5.07 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in Midatech Stock
If you are still planning to invest in Midatech Pharma PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Midatech Pharma's history and understand the potential risks before investing.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |